Digital solutions for early treatment of cognitive disabilities in chronic neurological diseases
Official title: EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069
Run by IRCCS Centro San Giovanni di Dio Fatebenefratelli · NCT06657274 · Data updated 2026-11-12
This study is testing a digital brain training program to see if it helps people with Mild Cognitive Impairment, subjective cognitive complaints, or Parkinson's Disease improve their thinking skills compared to a different type of brain activity.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | IRCCS Centro San Giovanni di Dio Fatebenefratelli Academic / other |
| Locations | 3 sites (Brescia, IT and 2 other locations) |
| Status | Recruiting |
| Started | December 9, 2024 |
| Main results expected | August 30, 2026 |
| Study ends | August 30, 2026 |
| Registry record updated | May 2, 2025 |
| Trial ID | NCT06657274 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 18 to 85 with a diagnosis of MCI, SCCs, or PD who meet specific cognitive assessment criteria.
✕Probably not a fit
Patients with significant psychiatric or medical conditions that could interfere with assessments or those currently undergoing rehabilitation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of a digital cognitive rehabilitation program for patients with Mild Cognitive Impairment (MCI), Subjective Cognitive Complaints (SCCs), and Parkinson's Disease (PD). A total of 60 participants will be recruited and divided into two groups: one receiving home-based cognitive telerehabilitation and the other receiving unstructured cognitive stimulation. Participants will undergo a series of assessments by neuropsychologists and will also have blood samples taken and Transcranial Magnetic Stimulation (TMS) applied at the beginning and end of the treatment. The study will assess cognitive improvements over a 5-week period and at a 3-month follow-up.
Why it matters
Potential benefit: If successful, this approach could enhance cognitive function and quality of life for patients with early-stage cognitive impairments.
How similar studies have gone: Previous studies have shown promise in using digital cognitive interventions for similar conditions, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of PD (Hoehn \& Yahr\<3); MCI (with CDR scale≤0.5, MMSE ≥24), and SCC (Subjective Cognitive Complaints); * Montreal Cognitive Assessment (MoCA) corrected score ≥17.36 * Education ≥ 5 years * Age eligible for the study: 18≤age≤85 * Native Italian speakers * Absence of marked hearing/visual impairment * All of the subjects will have normal or corrected-to-normal vision. * Agreement to participate by signing the informed consent form * Availability of a caregiver/study partner able to support the participant * No rehabilitation program in place at the time of enrolment or in the last 3 months before enrolment * Stable drug treatment (last 3 months), if any Exclusion Criteria: * Presence of any medical or psychiatric illness that could interfere with completing assessments; * Presence of any medical condition representing a contraindication to TMS.
Where it's running
-
IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli
Brescia, It, Italy Recruiting -
IRCCS Centro Neurolesi Bonino Pulejo
Messina, It, Italy Recruiting -
Fondazione Don Carlo Gnocchi - ONLUS, Milan
Milan, It, Italy Recruiting
Study contacts
- Study coordinator: Maria Cotelli, PhD
- Email: mcotelli@fatebenefratelli.eu
- Phone: +390303501457
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Using saliva and extracellular vesicles to diagnose neurodegenerative diseases
This study is testing a new way to diagnose neurodegenerative diseases like Alzheimer's and Parkinson's by analyzing saliva samples to see if it can help identify these conditions earlier and tailor treatments for patients.
-
Rural Veterans and Care Partners Walking Program
A virtual walking program is tested to see if it can help Veterans with mild cognitive impairment and their care partners in rural areas walk more each day.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Aging Brain Health Initiative in Fujian
This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.